Protagonist Therapeutics Inc (NASDAQ:PTGX) has received an average recommendation of “Hold” from the six analysts that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $37.00.
PTGX has been the topic of several recent research reports. BMO Capital Markets increased their price objective on Protagonist Therapeutics from $40.00 to $43.00 and gave the company an “outperform” rating in a research report on Tuesday, November 7th. Zacks Investment Research upgraded Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a research report on Saturday, November 11th. BidaskClub lowered Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 12th. Finally, Stifel Nicolaus initiated coverage on Protagonist Therapeutics in a research report on Monday, January 29th. They set a “buy” rating and a $32.00 price objective on the stock.
In related news, insider Richard S. Shames sold 3,529 shares of the firm’s stock in a transaction that occurred on Friday, December 22nd. The stock was sold at an average price of $20.50, for a total transaction of $72,344.50. Following the transaction, the insider now directly owns 3,529 shares in the company, valued at approximately $72,344.50. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Thomas P. O’neil sold 8,000 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $20.00, for a total value of $160,000.00. Following the transaction, the chief financial officer now owns 4,000 shares in the company, valued at $80,000. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 15,944 shares of company stock worth $319,839. 15.50% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. California State Teachers Retirement System grew its position in Protagonist Therapeutics by 8.5% during the 2nd quarter. California State Teachers Retirement System now owns 16,600 shares of the company’s stock worth $188,000 after acquiring an additional 1,300 shares during the last quarter. Bank of New York Mellon Corp grew its position in Protagonist Therapeutics by 5.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 27,626 shares of the company’s stock worth $313,000 after acquiring an additional 1,478 shares during the last quarter. Wells Fargo & Company MN grew its position in Protagonist Therapeutics by 60.8% during the 3rd quarter. Wells Fargo & Company MN now owns 9,565 shares of the company’s stock worth $169,000 after acquiring an additional 3,617 shares during the last quarter. TIAA CREF Investment Management LLC grew its position in Protagonist Therapeutics by 19.5% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 23,372 shares of the company’s stock worth $264,000 after acquiring an additional 3,812 shares during the last quarter. Finally, Teachers Advisors LLC grew its position in Protagonist Therapeutics by 33.1% during the 4th quarter. Teachers Advisors LLC now owns 21,593 shares of the company’s stock worth $449,000 after acquiring an additional 5,375 shares during the last quarter. Institutional investors and hedge funds own 47.54% of the company’s stock.
Protagonist Therapeutics (NASDAQ:PTGX) opened at $16.89 on Friday. The company has a market capitalization of $338.94, a PE ratio of -6.28 and a beta of -0.80. Protagonist Therapeutics has a 1 year low of $8.00 and a 1 year high of $23.75.
ILLEGAL ACTIVITY NOTICE: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/02/23/protagonist-therapeutics-inc-ptgx-receives-consensus-recommendation-of-hold-from-brokerages.html.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.